JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

JNJ

189.95

-1.17%↓

ABT

126.65

+0.22%↑

MDT

93.57

-0.46%↓

VEEV

294.18

+1.45%↑

A

148.19

+0.74%↑

Search

Zai Lab Ltd ADR

Aperta

SettoreSettore sanitario

26.49 -5.19

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

26.4

Massimo

28.23

Metriche Chiave

By Trading Economics

Entrata

7.7M

-41M

Vendite

3.5M

110M

Margine di Profitto

-37.032

Dipendenti

1,869

EBITDA

1.4M

-55M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+98.54% upside

Dividendi

By Dow Jones

Utili prossimi

6 nov 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1B

3.2B

Apertura precedente

31.68

Chiusura precedente

26.49

Notizie sul Sentiment di mercato

By Acuity

100%

0%

357 / 371 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 ott 2025, 20:49 UTC

Utili

Correction to Thermo Fisher Article on Oct. 22

23 ott 2025, 23:51 UTC

Discorsi di Mercato

WiseTech Bull Cheered by DSV's Freight Volumes -- Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 ott 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for Easing U.S.-China Tensions -- Market Talk

23 ott 2025, 23:37 UTC

Discorsi di Mercato

Gold Falls on Likely Further Unwinding of Long Positions -- Market Talk

23 ott 2025, 22:58 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

23 ott 2025, 22:57 UTC

Discorsi di Mercato

Woodside's Deal With Williams Eases Risks on Louisiana LNG Project -- Market Talk

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -2-

23 ott 2025, 22:49 UTC

Acquisizioni, Fusioni, Takeovers

How Trump Sparked a New Era of State Capitalism -- Barrons.com

23 ott 2025, 22:17 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 3rd Update

23 ott 2025, 21:41 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- 2nd Update

23 ott 2025, 21:05 UTC

Utili

Valero Earnings Show Why Refiners Are Energy's Big Winners This Year -- Barrons.com

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Tech, Media & Telecom Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato
Utili

Auto & Transport Roundup: Market Talk

23 ott 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

23 ott 2025, 20:35 UTC

Utili

These Stocks Moved the Most Today: Tesla, IBM, D-Wave Quantum, Dow Inc., Molina Healthcare, Las Vegas Sands, Southwest, and More -- Barrons.com

23 ott 2025, 20:28 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- Update

23 ott 2025, 20:15 UTC

Discorsi di Mercato
Utili

Global Commodities Roundup: Market Talk

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Adj EPS $1.71

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q Sales $5.52B

23 ott 2025, 20:10 UTC

Utili

Newmont Mining 3Q EPS $1.67

23 ott 2025, 20:09 UTC

Utili

Intel Stock Rises After Strong Earnings. CFO Says Chip Demand Will Outpace Supply Into Next Year. -- Barrons.com

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Global Equities Roundup: Market Talk

23 ott 2025, 20:07 UTC

Discorsi di Mercato
Utili

Ford Scrambles to Mitigate New Costs from Supplier Fire -- Market Talk

23 ott 2025, 20:07 UTC

Utili

Blackstone Looks to IPOs for Investment Exits -- Update

23 ott 2025, 20:05 UTC

Utili

Intel 3Q Gross Margin 38.2% >INTC

23 ott 2025, 20:04 UTC

Utili

Intel CFO: 'Current Demand Is Outpacing Supply, a Trend We Expect Will Persist Into 2026' >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Shows Progress in First Earnings Report Since U.S. Investment -- WSJ

23 ott 2025, 20:04 UTC

Utili

Intel: 4Q Guidance Excludes Altera >INTC

23 ott 2025, 20:04 UTC

Utili

Intel Sees 4Q Adj EPS 8c >INTC

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

98.54% in crescita

Previsioni per 12 mesi

Media 55.63 USD  98.54%

Alto 74 USD

Basso 39 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

6

Acquista

1

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

28.13 / 31.12Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat